HealthBlawg

David Harlow's Health Care Law Blog

    • Twitter
    • Facebook
    • LinkedIn
    • RSS
    • Email
  • About
  • Archives
  • Podcast
  • Press
  • Awards/Reviews
  • HIPAA
  • HCSM

QALY: measuring health care cost-effectiveness, defining health care coverage

June 12, 2007

Yesterday’s NY Times, in a special section on the business of health care, included an article on valuing years of a person’s life — the economic calculation of quality-adjusted life years.

The idea of QALY is to put a value on treatments that may not save lives but improve them. For example, if a blind person’s quality of life is “worth” 0.75 points per year, a treatment that would restore him to perfect vision — and raise his quality of life to 1 per year — is worth 0.25 per year of life. If the person lived another 30 years, the treatment would be worth 7.5 QALYs, or 30 times 0.25.

With QALYs, that treatment would produce the equivalent of keeping 10 patients on dialysis — whose lives are also “worth” 0.75 points per year — alive for a year.

In theory, QALYs offer a single figure that can measure value of every treatment, from drugs to surgeries to preventive care, like vaccines and cancer screenings.

These figures are developed through research interviews with individuals which yield fairly consistent results on the question of what a year in good health is worth ($100,000 – $300,000, according to Peter Neumann, the Tufts-NEMC expert — and grad school classmate of my wife’s — quoted in the Times). 

There has been a lot of discussion lately about whether the Massachusetts universal health care plan, or any national health care plan, can afford universal coverage without ratcheting down health care expenses.  We all know that the answer is no.  One point of view (which I share) is that we need to get people covered first, and then move on to cost control.

The next question is:  How do we decide what to pay for and how much will we pay for it?  A number of the presidential candidates would defer the question to a black-box institute.

The truth is, payors already enter into this sort of calculus in their benefit design and coverage decisions.  By way of example, see the recent discussion of this issue and a related NY Times article at Charlie Baker’s Let’s Talk Health Care — though he protests, "I’m not normally a NY Times kind of guy," and stakes out this function as the bailiwick of a future government body, not the current work of payors.

The black-box institute remains shrouded in mists of great expertise in the rhetoric of many participants in this discussion, because otherwise we’d have to be talking explicitly about the rationing of health care and, gee, we don’t do that in this country, do we?

Which brings us back to the QALY calculations.  We need to discuss metrics like these — and others, to be sure — if we are going to have a meaningful national conversation about health care costs.

— David Harlow       

Filed Under: Health care policy, Health Law, Massachusetts, Universal Health Care

you might also like:

  1. Peter Neumann, Director, Tufts Center for the Evaluation of Value and Risk in Health, speaks with David Harlow about the role of cost-effectiveness research in health care policy

  2. Tufts’ Peter Neumann and cost-effectiveness analysis – Better health through better measurement – Harlow On Healthcare

  3. News and notes on universal health care coverage at the state and federal levels

« Mandatory long term care insurance?
Health Wonk Review is up at the Health Business Blog »

Follow me on Twitter

David Harlow 💉😷 Follow 43,216 17,538

Mastodon @healthblawg@c.im #HealthCare #MedDevice #Compliance #Privacy @MyOmnipod #HIPAA #digitalhealth #HarlowOnHC #pinksocks Tweets are tweets No more no less

healthblawg
healthblawg avatar; David Harlow 💉😷 @healthblawg ·
5h 1639640904406544391

ICYMI> David Sand, CMO of ZeOmega, an #AI-infused engine for “payviders” — Harlow on Healthcare https://healthblawg.com/2022/10/david-sand-zeomega.html?utm_source=twitter&utm_medium=social&utm_campaign=ReviveOldPost #digitalhealth #hcldr #hitsm

Image for the Tweet beginning: ICYMI>  David Sand, CMO Twitter feed image.
Reply on Twitter 1639640904406544391 Retweet on Twitter 1639640904406544391 1 Like on Twitter 1639640904406544391 0 Twitter 1639640904406544391
healthblawg avatar; David Harlow 💉😷 @healthblawg ·
6h 1639630885497769985

The latest Harlow On Health Care Daily #HarlowOnHC #digitalhealth #healthcare #innovation #privacy #hcldr Thx: @rwneilljr @chidambara09 @SarahClarkBDM #digitalhealth #ai

Image for twitter card

AI's growing impact on echocardiography

cardiovascularbusiness.com Cardiology has the second largest number of FDA-cleared AI algorithms, and many of them are ...

paper.li

Reply on Twitter 1639630885497769985 Retweet on Twitter 1639630885497769985 0 Like on Twitter 1639630885497769985 0 Twitter 1639630885497769985
healthblawg avatar; David Harlow 💉😷 @healthblawg ·
12h 1639535190774276096

ICYMI> Stephen Sweriduk, CMO of Shields Health Care on the evolution of diagnostic imaging — Harlow on Healthcare https://healthblawg.com/2022/01/sweriduk-shields-healthcare.html?utm_source=twitter&utm_medium=social&utm_campaign=ReviveOldPost #digitalhealth #hcldr #hitsm

Image for the Tweet beginning: ICYMI>  Stephen Sweriduk, CMO Twitter feed image.
Reply on Twitter 1639535190774276096 Retweet on Twitter 1639535190774276096 1 Like on Twitter 1639535190774276096 0 Twitter 1639535190774276096
Load More
Follow me on Mastodon

HIPAAtools

Hipaatools

The HIPAA Compliance Toolkit

The Walking Gallery

The Walking Gallery

Quick Links

  • Home
  • Categories
  • Archives
  • Podcast Interviews
  • HIPAAtools
  • HIPAA Compliance
  • Health Care Social Media
  • Speaking
  • In the Press
  • Blogroll

David Harlow

David Harlow

HealthcareNOW Radio

Connect with David

  • Twitter
  • Facebook
  • LinkedIn
  • RSS
  • Email
  • Subscribe
  • Contact
  • Book Me: Speaking
  • About
  • The Harlow Group LLC
Copyright © 2006–2023
HealthBlawg is a publication of The Harlow Group LLC. See Copyright notice and disclaimer.
Fair use with attribution and a link is encouraged. Click for more on David Harlow.
[footer_backtotop text="Back to top" href="#"]